The Developmental Core provides mentoring support for junior investigators who are interested in pursuing an HIV research career.
The Developmental Core provides funding (up to $30,000; or $40,000 for proposals from CFAR scientific working groups) for one year for HIV research. The deadline for 2017 submissions has passed. Please check back for information on 2018 funding opportunities.
Awards are made for/to one of the following:
A senior mentor is required to assist junior Awardees in preparing the application, executing the project, preparing a manuscript, and writing a resulting larger grant proposal to the NIH. Research can be basic, translational, clinical, or social/behavioral, and can address treatment, transmission, or prevention. There are several opportunities during the year for Awardees to present their work.
*Junior investigators are defined as never having served as a PI on an R01 or R01 equivalent grant; holding a terminal degree (e.g. Ph.D., MD); eligible to serve as PI on NIH grant; and employed at UNC, FHI 360, RTI, or a NC HBCU.
Kate MacQueen, PhD, MPH
Dr. MacQueen is a Senior Scientist in Social & Behavioral Health Sciences at FHI 360 and Adjunct Associate Professor in in the UNC-CH School of Medicine Department of Social Medicine and in the Gillings School of Global Public Health’s Health Behavior Program. She has conducted research on the social, behavioral and ethical aspects of biomedical HIV prevention trials globally and domestically, including vaccines, microbicides and PrEP. Most recently her work includes leading LinCS 2 Durham, a five year NIH R01 project to help build support for new HIV prevention work with Durham’s black communities; an NIH R21 project on developing a framework for evaluating Good Participatory Practices in TB Drug Trials globally; and USAID funded research on women’s adherence to emerging HIV prevention technologies including tenofovir gel and vaginal rings. She also is a standing member of the NIH Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section [BSPH].
Ada Adimora, MD, MPH
Dr. Adaora Adimora is Professor of Medicine and Epidemiology at the University of North Carolina at Chapel Hill. Board certified in Internal Medicine and Infectious Diseases, she is a physician epidemiologist with more than 20 years of clinical experience in the treatment of patients with HIV disease. She studies the epidemiology of HIV and STIs. Her work has characterized the epidemiology of heterosexual HIV transmission among African Americans, highlighted the role of sexual network patterns in the spread of HIV, and underscored the importance of macroeconomic and social forces in racial disparities in the US HIV epidemic. She was selected by The Root as one 100 African American leaders “who are making extraordinary contributions.” She serves as Chair of the HIV Medical Association, chairs the NIH HIV Prevention Trials Network’s Women at Risk Committee, and is a member of the Women’s Research Initiative on HIV/AIDS, the NIAID Council, and the Presidential Advisory Council on HIV/AIDS.
Cathy Emrick, MPH
Ms. Emrick serves as the Core liaison for Developmental applications and Awardees. Ms. Emrick has an MPH in Health Behavior and Health Education from UNC, and works in both the UNC Center For AIDS Research (CFAR) Developmental Core as the Program Coordinator and the CFAR International Core as the Core Manager. She has focused on the HIV epidemic for the last 20 years, working in community-based organizations, state government, and research at UNC.
Request for Proposals for Developmental Awards
The UNC CFAR Developmental Core provides Developmental Awards and collaborative clinical-social science analysis awards to emerging HIV investigators for one year of research.
Q: What types of feedback does the CFAR Developmental Review Committee give to applicants?
A: There are definitely themes that we frequently see across applications, disciplines, and years. Common positive feedback includes:
· Project is significant, scientifically interesting
· The proposal includes strong mentors
· The hypothesis is plausible and novel
Common negative feedback includes:
· The proposal and intervention are too ambitious
· PI needs guidance with methods.
· The analysis plan was lacking.
· The sample size is too small
· No power calculations are discussed
· The intervention may be too diffuse
· No clear path to follow up NIH funding
Much of the negative feedback could be avoided by active engagement with the PI’s mentor during the application process. In addition, both the CFAR Biostatistics Core and Sonia Napravnik of the CFAR Clinical Core are willing to assist applicants with their methodology and/or analysis plans. The Social and Behavioral Science Core is also willing to help by looking at intervention ideas and social/behavioral methodology. We strongly recommend applicants utilize these resources before submitting their proposals – applications that have been through these steps prior to final submission tend to be more competitive.
Q: A mentor sounds useful. How do I get one of those?
A: If you have one or more already, feel free to use them. We understand the value of a mentoring team that may include a senior investigator who specializes in the science or methodology utilized by your proposal, another who knows your population or topic area, and perhaps another who has your dream career and can help you plan how to achieve one just like it. If, however, you have not yet found a mentor that is a good fit for you and your research goals, don’t worry – we can help! We could probably make some recommendations based on a conversation with you, but it would be even better if you had some ideas already. We suggest that you go to the NIH RePORTER and search for investigators based on location (ideally UNC, FHI, or RTI), topic area (e.g., HCV and HIV, medication adherence and HIV, or whatever you are interested in), and NIH Institute that you think is the best fit for you. After all, wouldn’t it be great to have a mentor that already knows the project officers, interests, quirks, etc., of your favorite Institute? If they have already figured out how to succeed in your area and Institute, they might be a good person to seek out for advice. Find a few people that fit those criteria if you can, and then email us with those names. We’ll facilitate your interactions with them and see if we can’t help get you one of those useful mentors.
Q: Are overhead/indirect costs or PI salary support allowed in the Developmental proposal budget?
A: It is our policy not to provide indirect costs or PI or faculty salary support at research-based colleges or universities. The UNC SOM similarly donates their share of the indirect costs back into the Award funds to maximize their reach.
While we ask that HBCUs waive indirect costs, HBCU proposal budgets may include up to two semesters of course buy-out.
FHI 360 and RTI PIs are expected to negotiate PI salary support levels and/or indirect charges to maximize the Award reach. For example, this might mean including a support letter saying indirects will be waived or that PI salary support will be partially or fully covered under another mechanism. Basically, we want to see that your institution is as invested in your professional development as we are.
Q: What’s a SWG and why do they get more money than the rest of us?
A: The UNC CFAR is committed to fostering interdisciplinary collaboration among research investigators, and provides the support and resources necessary for investigators to work together in pursuit of unique research topics. UNC CFAR’s Scientific Working Groups (SWGs) are comprised of investigators who share common research interests and goals, and participate in competitively funded research.
One of the CFAR’s missions is to support the work of our SWGs, so we like to see new interdisciplinary research come out of these groups and encourage that by offering them more money. Currently, our CFAR has three SWGs:
· HIV Cure (David Margolis, Chair)
· NC HIV Prevention (Heidi Swygard, Chair)
· PreP (Christopher Hurt, Chair)
If you like the idea of a larger Developmental Award and share their research interests, the SWGs are always open to new members!
Q: I’m a post-doc/fellow and really need some money for a great AIDS-related project. May I apply?
A: We appreciate post-docs/fellows and would love to help all of you but unfortunately our funds are limited. Since the CFAR’s continued funding depends in part on how successful our Developmental Awardees are at getting R and K level awards, and federal research funds are becoming harder to come by, we have to give preference to applications that will lead to an R or K level award and also ultimately lead to publication of Developmental data. In other words, while we are not currently completely ruling out post-doc applications at this time, strong preference will be given to junior faculty.
Q: I’m not a junior researcher, but I haven’t worked in HIV before. Don’t you want to help me?
A: Of course we do! In fact, we love to lure in senior investigators from other fields… I mean, help them expand their research interests. The application process is the same as for junior investigators, as are the required documentation and outcomes. If you have already been PI on an R01 for a project in HIV, however, you are already one of us and we cannot lure, ahem, fund you.
Q: My research interests align with NIH’s priorities and will lead to an R01, I’m sure of it. Is that all I need to say about that?
A: No, of course not! Tell us more – we want to hear all about it. To which institute will you be applying? Convince us that you and the NIH are soulmates, destined to come together in the relatively near future. We want a very specific funding path, a plan outlining how the proposed work will lead to NIH funding, a timeline for seeking such funding, the NIH institute or center from which you anticipate seeking funding, and the type of grant you plan to pursue (one page maximum, and not part of four page grant text limit). With which of NIH’s priorities does your project align? Your application must also include a separate document explaining how the proposed work is aligned with the NIH priorities. This document does not count toward the four-page grant text limit either.
Q: Talk to me about CFAR Administrative Supplements.
A: About once a year, NIH announces opportunities for CFAR Administrative Supplements. The RFA targets a short list of specific areas of HIV research that are generally up to about $100,000-$150,000 for one year. Each CFAR may submit one application per topic area to the NIH, so if more than one researcher is interested in a particular topic, we will do an internal review of letters of intent and choose one that can then move forward into a full application.
Q: That’s a lot more money than a CFAR Developmental Award. Can I apply for a CFAR Administrative Supplement?
A: Only if it is in an area of interest for this year’s Administrative Supplement RFA and you get the go-ahead from the CFAR leadership. Eligible applicants should also keep in mind that Supplement proposals must clear two hurdles at NIH – 1) they have to be strong enough in their science and methodology to be selected for funding; and 2) pay attention here – they have to be about HIV/AIDS! NIH will no longer fund non-AIDS projects with AIDS money. So if it is going through the Office of AIDS Research (as CFAR Administrative Supplements must), it had better have HIV or AIDS in its title. There are many STIs and IDs that are important in the world of HIV, but they are no longer going to be funded through the OAR. So if you want a CFAR Administrative Supplement, be sure you state clearly in the application and title that it is going to be HIV/AIDS research.
Q: What are the PI requirements for an Administrative Supplements?
A: They are similar to those of the Developmental Awards, i.e., you must be eligible to serve as a PI on an R level NIH grant, and you must be associated in some way with the CFAR through which you are applying (hence the requirement of the CFAR PI’s approval). The primary desired Supplement outcome is a larger, directly related NIH grant. The gold standard is an R01. We will be closely watching – and reporting on – Administrative Supplement PIs’ success(es), so that the NIH and Congress will see how important it is that they continue to provide CFAR and Supplemental funding.
Q: OK, so let’s say I get funding from a CFAR Developmental Award or a CFAR Administrative Supplement. What do YOU get out of it?
A: Well, if you can cure AIDS, that’d be good. But even if you can’t (yet), what we want is for you to succeed. Our goal is to help junior investigators build their HIV research careers and make a difference in this epidemic. As Charlie always said, we are training our replacements. As Kate says, we can see the light at the end of the tunnel now but the next generation of researchers is going to get to actually walk out into that light.
Of course, to justify our CFAR’s continued funding from NIH, we have to provide evidence that we are on the right track. As mentioned above, the primary desired outcome is always a larger, directly related NIH grant. The gold standard is an NIH R01 (or a less common “R01 equivalent”, i.e., R23, R29, or R37) grant, and that is what all of our Awardees and Administrative Supplement PIs should strive for. However, any post-Award funding that is directly related to your CFAR award is positive achievement and should be reported proudly back to the Developmental Core so that we can effectively brag about it to NIH and anyone else who will listen. An R21, for example, can be an intermediate step toward an R01 and may be easier to attain first. Funding from CDC or other sources is also nice, although less desirable as far as our needed outcomes as funding from NIH. In summary, smaller follow up funding is great, but keep your eye on the R01 as your ultimate goal.
We also need for you to share your CFAR research results with the scientific community. We are all partners in the fight against AIDS and sharing information makes us all stronger. Therefore, our other desired outcome for all CFAR-funded research is dissemination of results. The gold standard in this outcome category is publication in a peer review journal (citing the CFAR and linking it to our grant is required), but as an intermediate step, we accept the presentation of research at national and/or international conferences. Again, keep your eye on the prize – plan to publish.
Your mentor can play a key role in helping you achieve each of these outcomes. We can help as well. You have the support of an incredible HIV research community behind you – utilize us! In fact, even if you are not a Developmental Awardee or Administrative Supplement PI, if you are a junior investigator in the CFAR, we want to help you succeed.
Remember, we will be closely watching – and reporting on – your success(es), so that the NIH and Congress will see how important it is that they continue to provide CFAR and Supplemental funding.
The UNC Center for AIDS Research (CFAR) is soliciting proposals for small grants of up to $30,000 for one year to support emerging HIV Investigators (clinical, basic, and social scientists, including Pediatrics, OB-GYN, Internal Medicine, etc.) with terminal degrees who are seeking to fund new ideas in HIV research. Research can be basic, translational, clinical, biostatistical, or social/behavioral, and can address treatment, transmission, or prevention.
The purpose of these awards is to provide seed money for new ideas in HIV research that will lead to applications for outside independent NIH funding. The success of the UNC CFAR is measured by the number of subsequent NIH grants that our Developmental Awardees receive.
The deadline for 2017 submissions has passed. Please check back for information on 2018 funding opportunities.
Proposals will be reviewed by senior investigators on the basis of:
* Standard NIH criteria of significance, innovation, approach, environment, the ability of investigator to carry out award (defined below)
* Potential for future related NIH funding, including relevance of project to current NIH funding priorities (details below)
Proposals from women and minority investigators will be given special consideration in the review process.
Significance: Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Innovation: Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach: Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (exclusion) of children, justified in terms of the scientific goals and research strategy proposed?
Environment: Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Investigator ability: Are the PIs, collaborators, and other researchers well suited to the project? Do they have appropriate experience and training? If the project is collaborative or multi-PI, do the investigators have complementary and integrated expertise; is the leadership approach, governance, and organizational structure appropriate for the project? Is there evidence of strong and appropriate mentorship?
Potential for future related NIH funding: Is there a clear vision for how the proposed work will build toward independent research that is aligned with NIH HIV funding priorities for the investigator?
EXPECTED PROJECT OUTCOMES
Peer-review publication and independent NIH funding (i.e., R21, R01, and R01-equivalent awards).
CURRENT NIH PRIORITIES
In Fall 2015, NIH released a list of its funding priorities for the next three to five years at NOT-OD-15-137, along with a related statement from NIMH that describes their impact on grant funding. NIDA has now released its 2017 priorities as well. Given that the CFAR will ultimately be judged on the success of its Awardees (defined by NIH as independent NIH funding), Developmental applications will be prioritized based on the alignment of proposals with NIH funding priorities.
All Developmental applications must include a separate document explaining how the proposed work is aligned with the NIH priorities. This document does not count toward the four-page grant text limit. If you have any questions or concerns about how your proposed research aligns with the NIH priorities, please contact us and we will work with you and/or identify others who can work with you on this issue.
We are especially interested in applications that are responsive to or aligned with the UNC CFAR priorities (Curing AIDS and NC HIV Prevention), as well as international HIV research applications. However, applications need not be limited to these areas.
1) PI must have an affiliation with UNC-Chapel Hill, FHI 360, RTI International, or a North Carolina-based historically black college or university (HBCU). International investigators and other NC Triangle-based investigators with a connection to one of the above are also eligible.
2) Applicants must have a terminal degree (e.g., PhD, MD, PharmD, etc.).
3) Applicants must be eligible to serve as the Principal Investigator (PI) on National Institutes of Health (NIH)-funded grants. Accordingly, university-based applicants must be either a faculty member or a postdoc who has received departmental approval to serve as an NIH PI; postdocs applying for this award must also partner with a faculty co-PI.
4) Applicants must be new or early stage investigators or established investigators in non-HIV fields who have never received an R01 or R01-equivalent (R01, R23, R29, and R37) award in HIV/AIDS. Established investigators will only be considered if they are new to HIV research.
5) UNC-CH-affiliated applicants may not use award funds to support faculty or post-doc salary, conference travel, or food/drinks.
6) Investigators who have already received a UNC CFAR Developmental Award are unlikely to be funded a second time. Previous Awardees should contact the Developmental Core before submitting a new application.
7) International applicants must be actively collaborating with at least one mentor who is faculty at UNC-CH or a UNC CFAR member at an affiliated institution (FHI 360, RTI) in the development of their application. This must be evident in the application itself, including appropriate letters of support.
8) Junior applicants who are not international applicants must be actively collaborating with a senior investigator in the HIV field (i.e., someone with previous HIV-related independent NIH funding). This must be evident in the application itself, including appropriate letters of support.
9) Senior investigators who are new to the HIV field must be consulting or collaborating with a senior HIV investigator. This must be evident in the application itself, including appropriate letters of support.
Please feel free to reach out to us if you need help identifying mentors and collaborators.
1) Project proposal up to four pages (single-spaced, 11 point Arial font) including Specific Aims, Significance, Innovation, and Approach sections
2) A separate References cited section
3) For junior and international applicants, identification of proposed mentor – a senior faculty member with experience conducing HIV-related research – and explanation of their role on the project, starting with during the application process (this can be a separate page)
4) Separate budget and budget justification section
5) NIH biosketch for all key personnel
6) Statement of how the application fits into an NIH high priority topic of research
7) Plan outlining how the proposed work will lead to NIH funding, a timeline for seeking such funding, the NIH institute or center from which they anticipate seeking funding, and the type of grant they plan to pursue (one page maximum, not part of four page grant text limit)
8) Letter of support from the applicant’s proposed mentor, outlining the mentor’s proposed role in the project and connection to the applicant.
9) Other letters of support are strongly encouraged if applicable (e.g., to verify access to clinic populations, for collaborators, etc.), and a cover letter may be submitted if desired.
For items 4 and 5, use the forms “Detailed Budget for Initial Budget Period,” and “Biographical Sketch Format Page” which can be found here. An example biosketch can also be found on this NIH website.
Additional notes: Please document eligibility to apply for CFAR Developmental funds as a faculty member/researcher or post-doc working as a co-PI with a faculty member of an eligible institution. This documentation can be part of a letter of support, either from the mentor if appropriate, department chair, etc.
Applicants are strongly encouraged to consult the CFAR Biostatistics Core and/or Tania Caravella, the CFAR Regulatory Head, with any relevant questions during the application preparation process. We have found that such consultations often significantly strengthen proposals.
New this year! Early in their funding period, Developmental Awardees will be required to present long-term research plans related to their Developmental research at a forum to senior CFAR investigators. Resulting feedback and questions will then inform the implementation of their research, with the goal of stronger preliminary data and analysis in order to ultimately support a successful NIH funding application.
Up to $30,000 for one year; $40,000 if the application is a collaboration coming out of a CFAR Scientific Working Group (include a letter of support from the SWG chair). Because funds release and study implementation is contingent on UNC IRB, international ethics committee (if applicable), and NIH approvals, the funding will only be initiated once all necessary approvals are obtained and all forms are submitted to the CFAR Developmental Core, and can only be guaranteed through July 31, 2018. Awardees will have a deadline of one month from notification of award to submit applications to their IRB(s) and all non-IRB forms to the Developmental Core. Subsequent NIH approval can take up to four months (worst case scenario).
Funding will be available no earlier than August 1, 2017, and may be later, depending on how long the approval processes take for a given application.
OTHER CFAR SERVICES
Besides direct funding, the UNC CFAR has numerous Cores (Virology/Immunology/Microbiology Core, Analytical Chemistry/Clinical Pharmacology Core, Clinical Core, Social and Behavioral Science Core, International Core, and Biostatistics Core) that can assist with HIV-related research projects. They have the ability to do assays (Virology, Pharmacology), assist with consultation in developing questionnaires (Clinical, Social and Behavioral), and reviewing any grants you plan to submit to outside agencies. Descriptions of these services can be found on the UNC CFAR website, where you can also submit a request for those services on individual Core pages.
GRANT WRITING GUIDANCE
Excellent general guidance on grant-writing from NIH can be found here.
For additional information, please contact Cathy Emrick (email@example.com). All questions are welcome.
The University of North Carolina Center for AIDS Research (CFAR) is soliciting proposals for small grants to support clinical, basic or social science junior investigators or experienced investigators new to HIV research interested in evaluating innovative social and behavioral questions in HIV infection using existing data from specific large CFAR projects.
The purpose of these awards is to increase scientific contributions by facilitating secondary data analysis and supporting external grant application submissions to address research questions related to social and behavioral aspects of the HIV/AIDS epidemic. The seed money provided with these awards may be used for investigators to: (1) support appropriate materials or non-faculty personnel (i.e. graduate research assistants) to assist with data cleaning, management and/or secondary data analyses; (2) to collect limited supplemental social and/or behavioral data (such as conducting qualitative interviews); and (3) to provide administrative support for manuscript preparation. Ideally, results of proposed analyses would be used as preliminary study results for a larger study proposal.
Projects must involve analyses of data from one or more of the following CFAR projects:
The UNC HIV Clinical Cohort (UCHCC) study
UCHCC includes patients receiving HIV care at UNC since 1996, with >4,000 patients enrolled. Approximately 30% are women, 33% White, 58% Black, and 7% Hispanic; median age at first visit is 37 years, with over 20,000 accrued person-years and 6 years median follow-up. Data includes electronic downloads of demographics, laboratory values, and visit data. Medical record reviews are completed, including HIV risk factors, health maintenance, medications (including antiretrovirals), diagnoses, antiretroviral resistance, hospitalizations, and external records (e.g., vital status). UCHCC patients complete an in-depth, in-person interview, with data on HIV risk behaviors, socio-demographics, HIV testing and access to care, antiretroviral therapy use, social support, and co-morbidities. Additionally patients complete a patient reported outcomes (PRO) survey, including data on antiretroviral therapy adherence, mental health and substance abuse, and quality of life measures. Specimens (plasma, cell pellets and PBMCs) are collected and stored. For the study overview please visit this page and for additional information about the data and data approval process please contact Sonia Napravnik.
CFAR Network of Integrated Clinical Systems (CNICS)
The CFAR Network of Integrated Clinical Systems (CNICS) research network is the first electronic medical records-based network to integrate clinical data from the large and diverse population of HIV-infected persons in the modern HAART era. CNICS supports HIV clinical outcomes and comparative effectiveness research using data collected from patients receiving care at one of 8 US-funded Center for AIDS Research (CFAR) sites. As of May 2013, CNICS contained 27,477 patients; 81.8% male and 18.2% female. Unlike data collected in structured interviews or retrospective medical record review, CNICS captures a broader range of information associated with the rapidly changing course of HIV disease management. The flexibility of the CNIC consortium enables researchers to address scientific questions that cannot be answered through other collaborative cohorts. Patient data includes validated outcomes, longitudinal resistance data, patient-reported outcomes and readily available biological specimens. For the study overview please visit this page and for additional information about the data and data approval process please contact Sonia Napravnik.
Women’s Interagency HIV Study (WIHS)
The Women’s Interagency HIV Study (WIHS) is a multicenter longitudinal study funded by the NIH to investigate the progression of HIV disease in women. Established in 1993, WIHS has enrolled over 4,000 women with approximately 3,000 in active follow-up (70% HIV+, 30% HIV-). The core portion of the study consists of bi-annual visits that include 1) A structured interview: medical and health history, obstetric/gynecological and contraceptive history, health care utilization, engagement in care, sexual behavior, drug and alcohol use, psychosocial factors and lifetime history of abuse; 2) A physical and gynecologic exam: anthropometric measurements, bioelectrical impedance analysis, ankle brachial index, cervical exam and pap-smear; and 3) Specimen collection and laboratory testing: urine, blood and CVL collection. Routine labs include: viral load, CD4, urinalysis, basic chemistries, STD testing (baseline only), lipid/metabolic panel (annually). For the study overview please see this page and for additional information about the data and data approval process please contact Catalina Ramirez.
Community and Prison Health Study
The Community and Prison Health Study is a retrospective project which has linked UNC HIV Clinical Cohort (UCHCC) study data and incarceration data to explore health outcomes among HIV-positive individuals in the community and in prison. In addition to UCHCC data (described above), data routinely collected among state prisoners include dates of prison entry and exit, mental health and medical diagnoses, antiretroviral prescriptions, and viral load labs. For additional information about this project, please contact David Rosen.
The Sexual Acquisition and Transmission of HIV Cooperative Agreement Program (SATHCAP) is a multisite (Raleigh/Durham, Los Angeles, Chicago) study designed to assess the role of drug use in the sexual transmission of HIV from traditional high-risk groups, such as men who have sex with men (MSM) and drug users (DU), to lower risk groups, such as non-drug-using sexual partners. SATHCAP conducted a cross-sectional study across 3 US sites using a respondent-driven sampling (RDS) sampling approach, a common questionnaire, and similar biological testing. The goal of the sampling approach was to recruit an RDS sample of MSM, DU, and individuals who were both MSM and DU (MSM/DU), as well as a sample of sex partners of MSM, DU, and MSM/DU, and sex partners of sex partners. Respondents were asked questions about their sexual relationships with their partners, drug use, and methods of sharing drugs. In addition to survey and network data available from all 3 sites, specimens from the Raleigh/Durham site are available for additional analysis. For more information about SATHCAP, please contact Dr. Bill Zule.
1) These awards are limited to persons affiliated with UNC-Chapel Hill, FHI 360, RTI International, and North Carolina-based historically black colleges and universities (HBCUs).
2) Applicants must have a terminal degree.
3) Applicants must be eligible to serve as the Principal Investigator (PI) on National Institutes of Health (NIH)-funded grants. Accordingly, university-based applicants must be either a faculty member or a postdoc who has received departmental approval to serve as an NIH PI; postdocs applying for this award must also partner with a faculty co-PI.
4) Experienced researchers will only be considered if they are new to HIV research.
5) Only HBCU investigators may use award funds to support their salary or travel.
LETTER OF INTENT
Check back for information on the 2017 RFA in January.
The letter should consist of a one (1) paragraph project summary describing the data source, specific research question(s), and proposed mentor. Applicants will be contacted as soon as possible with feedback to increase the likelihood that proposals are feasible and responsive to the goals of this request for proposals, as described above.
The deadline for 2017 submissions has passed. Please check back for information on 2018 funding opportunities.
Applications should include the following:
1) a two page (single-spaced, 11 point Arial font) project proposal including Specific Aims, Significance, Innovation, and Approach sections
2) a separate References section
3) a proposed mentor—a senior faculty member with experience conducing HIV-related research—and their role on the project
4) a budget and budget justification
5) a biosketch
For items 4 and 5, use the forms “Detailed Budget for Initial Budget Period,” and “Biographical Sketch Format Page” (which can be found here). If applicants fail to identify a potential mentor, one may be recommended by the review committee.
Up to $5,000 for one year. Because data transfer is contingent on both IRB approval and (for some datasets) formal approval by the entity responsible for the proposed dataset, the funding will only be initiated once the necessary approvals are obtained and will continue for one year from that date. Awardees will have a deadline of three months from notification of award to submit their IRB applications and proposals to appropriate entities for approval.
The deadline for 2017 submissions has passed. Please check back for information on 2018 funding opportunities. All submissions should be emailed as an attachment to: firstname.lastname@example.org.
REVIEW PANEL CRITERIA
Originality, scientific merit, ability of investigator to carry out award, and potential for future funding. Priority will be given, but not limited, to studies that address topics of health disparities and/or vulnerable populations. Examples of previously funded studies include:
- “The HIV Care Continuum: CD4 and Viral Load Measures as Proxies for HIV Care Visits”
- “Race, Place, and Antiretroviral Therapy Adherence”
- “Understanding barriers to timely presentation to HIV care in North Carolina”
- “Intimate partner violence, health behaviors and outcomes in a cohort of HIV-infected women”
Bayraktar U.D., Diaz L.A., Ashlock B., Toomey N., Cabral L., Bayraktar S., Pereira D., Dittmer D.P., Ramos J.C. (2014). Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. Leuk Lymphoma. 55(4):786-94.
Flax VL, Bentley ME, Combs GF Jr., Chasela CS, Kayira D, Tegha G, Kamwendo D, Daza EJ, Fokar A, Kourtis AP, Jamieson DJ, van der Horst CM, Adair LS. Plasma and breastmilk selenium in HIV-infected Malawian mothers are positively associated with infant selenium status but are not associated with maternal supplementation: results of the BAN study. Am J Clin Nutr 2014;99:950-6. PMC3953887.
Gopal S, Patel MR, Achenbach CJ, Yanik EL, Cole SR, Napravnik S, Burkholder GA, Mathews WC, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Richards KL, Eron JJ. (2014a) Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. Clin Infect Dis. [Epub ahead of print] PMCID in process
Maliwichi M, Rosenberg NE, Macfie R, Olson D, Hoffman I, van der Horst CM, Kazembe PN, Hosseinipour MC, McCollum ED. (2014) CD4 count outperforms World Health Organization clinical algorithm for point-of-care HIV diagnosis among hospitalised HIV-exposed Malawian infants. Trop Med Int Health. Epub ahead of print.
McCollum ED, Preidis GA, Maliwichi M, Olson D, McCrary LM, Kazembe PN, Horst Cv, Hoffman I, Hosseinipour MC. (2014) Clinical versus rapid molecular HIV diagnosis in hospitalized African infants: a randomized controlled trial simulating point-of-care infant testing. J Acquir Immune Defic Syndr. 66(1):e23-30. PMC in process.
Parobek CM, Jiang LY, Patel JC, Alvarez-Martínez MJ, Miro JM, Worodria W, Andama A, Fong S, Huang L, Meshnick SR, Taylor SM, Juliano JJ. A Multilocus Microsatellite Genotyping Array to Investigate the Genetic Epidemiology of Pneumocystis jirovecii. J Clin Microbiol. 2014 [Epub ahead of print]
Rahangdale L, Stewart A, Stewart RD, Badell M, Levison J, Ellis P, Cohn SE, Dempf MC, Lazenby GB, Tandon R, Rana A, Nguyen LM, Sturdevant MS, Cohan D, HOPES (HIV and OB Pregnancy Education Study). (2014). Predictors of unplanned pregnancy among women living with HIV in the United States. J Acquir Immune Defic Syndr. 2014; 65(3):306-11. PMC3927156
Dennis AM, Wheeler JB, Valera E, Hightow-Weidman L, Napravnik S, Swygard H, Barrington C, Eron JJ (2013). HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States. AIDS Care, 25(10), 1298-307.
Flax VL, Bentley ME, Chasela CS, Kayira D, Hudgens MG, Kacheche KZ, Chavula C, Jamieson DJ, van der Horst CM & Adair LS. Lipid-based nutrient supplements are feasible as a breastmilk replacement for HIV-exposed infants from 24-48 weeks of age. J Nutr, 2013;143:701-7. PMC3738238.
Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Eron JJ, Richards KL. (2013a) Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 105(16):1221-9. PMID: 23892362
Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Richards KL, Eron JJ. (2013b) Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS. 27(15):2365-73. PMID:23736149
Henley C, Forgwei G, Welty T, Golden M, Adimora A, Shields R, Muffih PT (2013). Scale-up and case-finding effectiveness of an HIV partner services program in Cameroon: an innovative HIV prevention intervention for developing countries. Sex Transm Dis. 40(12), 909-14.
Kendig CE, McCulloch DJ, Rosenberg NE, Samuel JC, Mabedi C, Shores CG, Hosseinipour MC, Matoga M, Charles AG (2013). Prevalence of HIV and Disease Outcomes on the Medical and Surgical Wards at Kamuzu Central Hospital, Lilongwe, Malawi. Trop Med Health, 41(4), 163-70. PMC3883455
Paz-Bailey G., Miller W., Shiraishi R.W., Jacobson J.O., Abimbola T.O., & Chen S.Y. (2013) Reaching Men Who Have Sex with Men: A Comparison of Respondent-Driven Sampling and Time-Location Sampling in Guatemala City. AIDS Behav, 17:3081–3090. PMCID in process.
Chasela, C.S., Wall, P., Drobeniuc, J., King, C.C., Teshale, E., Hosseinipour, M.C., Ellington, S.R., Codd, M., Jamieson, D.J., Knight, R.J., Fitzpatrick, P., Kourtis, A.P., Hoffman, I.F., Kayira, D., Mumba, N., Kamwendo, D.D., Martinson, F., Powderly, W., van der Horst, C., Kamili, S.; the BAN team. (2012). Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: The BAN study. J Clin Virol, 54, 318-20. PMC3652577
Hernandez, A.M., Zule, W.A., Karg, R.S., Browne, F.A., Wechsberg, W.M (2012). Factors That Influence HIV Risk among Hispanic Female Immigrants and Their Implications for HIV Prevention Interventions. Int J Family Med. 2012:876381. Epub. PMC3296155
Kincaid, C., Jones, D.J., Sterrett, E., McKee, L. (2012). A review of parenting and adolescent sexual behavior: the moderating role of gender. Clin Psychol Rev, 32, 177-88. doi: 10.1016/j.cpr.2012.01.002
McCollum, E.D., Johnson, D.C., Chasela, C.S., Siwande, L.D., Kazembe, P.N., Olson, D., Hoffman, I., van der Horst, C., Hosseinipour, M.C. (2012). Superior Uptake and Outcomes of Early Infant Diagnosis of HIV Services at an Immunization Clinic Versus an “Under-Five” General Pediatric Clinic in Malawi. J Acquir Immune Defic Syndr, 60, e107-10. PMC3412370
Meier BM, Pardue C, London L. (2012) Implementing Community Participation Through Legislative Reform: A Study of the Policy Framework for Community Participation in the Western Cape Province of South Africa. BMC Int Health Hum Rights. 12:15. PMC3532148
Tucker, J.D., Walensky, R.P., Yang, L.G., Yang, B., Bangsberg, D.R., Chen, X.S., Cohen, M.S. (2012a). Expanding provider-initiated HIV testing at STI clinics in China. AIDS Care. [Epub ahead of print] PMC3400702
Tucker, J.D., Yang, L.G., Yang, B., Young, D., Henderson, G.E., Huang, S.J., Lu, H.K., Chen, X.S., Cohen, M.S. (2012b). Prior HIV testing among STD patients in Guangdong Province, China: opportunities for expanding detection of sexually transmitted HIV infection. Sex Transm Dis. 39, 182-7. PMC3282013
Braun, M., Kabue, M.M., McCollum, E.D., Ahmed, S., Kim, M., Aertker, L., Chirwa, M., Eliya, M., Mofolo, I., Hoffman, I., Kazembe, P.N., van der Horst, C., Kline, M.W., Hosseinipour, M.C. (2011). Inadequate coordination of maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr, 56, e122-8. PMC3112277
Cené, C.W., Akers, A.Y., Lloyd, S.W., Albritton, T., Powell Hammond, W., & Corbie-Smith, G. (2011). Understanding social capital and HIV risk in rural African American communities. J Gen Intern Med, 26, 737-744. doi: 10.1007/s11606-011-1646-4
Gay, C., Dibben, O., Anderson, J.A., Stacey, A., Mayo, A.J., Norris, P.J., Kuruc, J.D., Salazar-Gonzalez, J.F., Li, H., Keele, B.F., Hicks, C., Margolis, D., Ferrari, G., Haynes, B., Swanstrom, R., Shaw, G.M., Hahn, B.H., Eron, J.J., Borrow, P., Cohen, M.S. (2011). Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy. PLoS One, 6, e19617. PMC3091862
Kincaid, C.Y., Jones, D.J., Gonzalez, M., Payne, B.K., DeVellis, R. (2011). The Role of Implicit Measurement in the Assessment of Risky Behavior: A Pilot Study with African American Girls. Journal of Child and Family Studies. J Child Fam Studies, 21, 799-806. doi: 10.1007/s10826-011-9537-1
McCollum, E.D., Preidis, G.A., Golitko, C.L., Siwande, L.D., Mwansambo, C., Kazembe, P.N., Hoffman, I., Hosseinipour, M.C., Schutze, G.E., Kline, M.W. (2011). Routine inpatient human immunodeficiency virus testing system increases access to pediatric human immunodeficiency virus care in sub-Saharan Africa. Pediatr Infect Dis J, 30, e75-81. PMCID in process
Ramos JC, Sin SH, Staudt MR, Roy D, Vahrson W, Dezube BJ, Harrington W Jr, Dittmer DP. Nuclear factor kappa B (NFkB) pathway associated biomarkers in AIDS defining malignancies. Int J Cancer. 2011 Jul 25. doi: 10.1002/ijc.26302. [Epub ahead of print]
Brown, L.B., Krysiak, R., Kamanga, G., Mapanje, C., Kanyamula, H., Banda, B., et al. (2010). Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis, 37, 169-172. doi: 10.1097/OLQ.0b013e3181bf575c
Chasela, C.S., Hudgens, M.G., Jamieson, D.J., Kayira, D., Hosseinipour, M.C., Kourtis, A.P., et al. (2010). Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission. New Engl J Med, 362, 2271-2281.
Corbett, A.H., Hosseinipour, M.C., Nyirenda, J., Kanyama, C., Rezk, N.L., Mkupani, P., et al. (2010). Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Antivir Ther, 15, 83-90. PMC2867092
Corbie-Smith, G., Akers, A., Blumenthal, C., Council, B., Wynn, M., Muhammad, M., et al. (2010). Intervention mapping as a participatory approach to developing an HIV prevention intervention in rural African American communities. AIDS Educ Prev, 22, 184-202. PMC3037273
Firnhaber, C., Van Le, H., Pettifor, A., Schulze, D., Michelow, P., Sanne, I.M., et al. (2010). Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control, 21, 433-443. PMC2835728
Gherghe C, Lomob T, Leonard CW, Datta SAK, Bess JW, Gorelick RJ, Rein A and Weeks KM. (2010) Definition of a high-affinity Gag recognition structure mediating packaging of a retroviral RNA genome. Proc Natl Acad Sci USA. 107:19248-19253.
Hobbs, M.M., Steiner, M.J., Rich, K.D., Gallo, M.F., Warner, L., & Macaluso, M. (2010). Vaginal swab specimen processing methods influence performance of rapid semen detection tests: A cautionary tale. Contraception, 82(3), 291-295. PMC2921540
Masharsky AE, Dukhovlinova EN, Verevochkin SV, Toussova OV, Skochilov RV, Anderson JA, Hoffman I, Cohen MS, Swanstrom R, and Kozlov AP. (2010). A significant transmission bottleneck among newly and recently HIV-1 infected injection drug users in St. Petersburg, Russia. J Infect Dis 20:1697-1702.
Meyer, W., Costenbader, E.C., Zule, W.A., Otiashvili, D., & Kirtadze, I. (2010). ‘We are ordinary men’: MSM identity categories in Tbilisi, Georgia. Cult Health Sex, 12, 955-971. doi: 10.1080/13691058.2010.516370.
Rhodes, S.D., Hergenrather, K.C., Duncan, J., Vissman, A.T., Miller, C., Wilkin, A.M., et al. (2010). A pilot intervention utilizing Internet chat rooms to prevent HIV risk behaviors among men who have sex with men. Public Health Rep, 125 (Supp), 129-137. PMC2788406
Scheyett, A., Parker, S., Golin, C., White, B., Davis, C.P., & Wohl, D. (2010). HIV-infected prison inmates: depression and implications for release back to communities. AIDS Behav, 14, 300-307. PMC2888156
Sena, A.C., Hammer, J.P., Wilson, K., Zeveloff, A., & Gamble, J. (2010). Feasibility and acceptability of door-to-door rapid HIV testing among Latino immigrants and their HIV risk factors in North Carolina. AIDS Patient Care STDS, 24, 165-173. PMC2864055
Required Documents from new Developmental Awardees:
Final Developmental application, including budget and budget justification
.pdf copy of IRB approvals from any collaborating institutions as well as UNC
Photo of PI for CFAR website
Documentation of human subjects training for all study personnel
All informed consent forms